Beam Therapeutics inks deal with Pfizer worth up to $1.35B
January 10, 2022 at 06:18 AM EST
The Cambridge-based gene-editing firm has signed a four-year deal worth up to $1.35 billion with pharmaceutical giant Pfizer Inc.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|